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Background: The expression of CK19 in primary hepatocellular carcinoma (HCC) is associated with a poor outcome.
However, few studies have investigated the expression profile of CK19 in regional lymph nodes (LNs) of HCC after
hepatic resection. The purpose of this study was to evaluate the expression of CK19 in primary liver tumor and
regional LNs of HCC with and without lymph node metastasis (LNM).
Methods: The expression of CK19 in patients with (n = 16) and without LNM (n = 26) was examined using
immunohistochemical staining. Both the primary tumor and LN specimen were studied for their CK19 expression.
Clinico-pathological variables and prognostic significance were analyzed.
Results: Immunopositivity of CK19 in primary liver tumor was significantly correlated with LNM (P = 0.005) and
tumor non-encapsulation (P <0.005). Univariate analysis showed that CK19 expression in primary liver tumor, CK19
expression in regional LN, vascular invasion, daughter nodules, positive resection margin and American Joint
Committee on Cancer (AJCC) tumor stage significantly decreased overall survival. Multivariate analysis demonstrated
that daughter nodules (P = 0.001) and CK19 expression in regional LN (P = 0.002) were independent prognostic
factors for overall survival.
Conclusions: This study showed that CK19 expression in regional LN of HCC was associated with LNM and an
extremely poor outcome after operation. It is of clinical significance to identify these patients at risk for more
aggressive HCC, and multi-modality treatment could be helpful to improve their dismal outcome.
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Hepatocellular carcinoma (HCC) is the most common
primary malignancy of the liver with an estimated
annual death incidence of approximately 600,000 world-
wide. In Taiwan, it is the second most common cause of
cancer death and causes more than 7,500 deaths each
year [1]. Surgical resection remains the most effective
therapy in selected patients, but approximately 75% of
patients with HCC have advanced unresectable diseases
upon presentation. Compared with other malignancies* Correspondence: mingchin2000@gmail.com
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reproduction in any medium, provided the orsuch as lung cancer, esophageal cancer, renal cancer,
gastric cancer, and intra-hepatic cholangiocarcinoma,
the incidence of lymph node metastasis (LNM) in
primary HCC is very low, and the prognosis is poor
when LNM occurs [2-11]. Nevertheless, despite this
poor outcome, previous study has documented that the
5-year overall survival rate of HCC with LNM after
hepatectomy and lymph node dissection was 13.6%, and
5 out of 22 patients had survival of more than two years
[12]. Due to LNM’s dismal role in prognosis, it is
imperative to identify those patients at risk for LNM for
more aggressive treatment and detailed examination.
Cytokeratin19 (CK19) is a biliary epithelial cell marker
and is generally expressed in intrahepatic cholangiocar-
cinoma (ICC) cells [13]. Studies have shown that the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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poorer outcome [14]. There have also been studies dem-
onstrating that CK19 expression in primary HCC is a
significant risk factor for developing LNM [15-17]. How-
ever, few studies have investigated the expression profile
of CK19 in regional lymph nodes (LN) of HCC after
hepatic resection. HCC with CK19 expression, specula-
tively, may be a special subtype of HCC with distinct
clinical behavior from HCC without CK19 expression.
Therefore, the purpose of this study was to examine the
expression of CK19 in primary liver tumor and regional
LN of HCC with and without lymph node metastasis.
The correlation between CK19 expression in LN and
LNM was determined. Clinico-pathological variables
were also investigated to explore the impact of CK19
expression on survival outcome. Finally, the significance




For the years from 1982 to 2010, records of patients
with histological proven primary HCC from the Cancer
Registry of the Cancer Center, Chang Gung Memorial
Hospital, Linkou, Taiwan, were retrospectively reviewed.
Only patients who underwent curative hepatectomy by
the same surgical team were eligible for this study, and
their clinico-pathological data were retrieved from the
prospectively collected database. The following variables
were included in the analyses: age, gender, cigarette
smoking, alcohol consumption, hepatitis B virus (HBV)
infection, anti-hepatitis C virus antibody (anti-HCV) level,
alkaline phosphotase level, bilirubin level, preoperative
alpha-fetoprotein level, Child-Pugh classification, tumor
size, tumor-LNM status, tumor encapsulation, histological
grade, fatty liver, resection margin, and mortality. The
study endpoint was 30 June 2010, and tumor staging was
based on the 6th edition of AJCC TNM staging system for
HCC. This study was approved by the Institutional Review
Boards (IRB 99-1127B) of Chang Gung Memorial Hospital
(CGMH).
The indications for surgery included a lack of cancerous
thrombi in the main trunk of the portal vein, no distant
metastasis to other organs, absence of ascites or jaundice,
and a technically operable main tumor in the preoperative
evaluation [18]. Suspected LNM restricted to the hepato-
duodenal ligament, detected by a preoperative image
study, was defined as HCC operable by experienced
surgeons, and hepatectomy combined with lymph node
dissection was performed. For resectable tumors, the
hepatic hilum and hepatoduodenal ligament were carefully
examined and palpated to detect any enlarged lymph
nodes by the chief surgeons. Lymphadenectomy was
performed if there were enlarged lymph nodes. Forty-twopatients who received lymph node dissection or sampling
were selected from our database for this study. Of them,
sixteen patients (38.1%) had pathologically proven LNM
and 26 (61.9%) did not have LNM. Absence of LNM was
confirmed by the following three criteria: (1) negative
reports of preoperative computed tomography scans,
interpreted by experienced radiologists; (2) no intra-
operative detectable enlarged lymph nodes, proven by
experienced hepatobiliary surgeons; and (3) negative post-
operative pathological report of LNM in the resected
specimen, examined by pathologists who were experts in
hepatology.
Immunohistochemistry
Formalin-fixed and paraffin-embedded resection spe-
cimens were sectioned to 4µm in thickness and
deparaffinized, rehydrated, and processed for antigen
retrieval. The slides were further incubated with diluted
(1:100) monoclonal antibody to CK19 (Abcam, San
Francisco, CA, USA) at room temperature for 1 hour.
After incubation, the slides were washed three times in
phosphate-buffered saline, incubated with a horse reddish
peroxidase conjugated antibody (ZYMED, San Francisco,
CA, USA) at room temperature for 10 minutes, and then
developed by treatment with 3,3-diaminobenzidine
(Dako North America, Inc. Carpinteria, CA, USA) at
room temperature for another 10 minutes. Inde-
pendent experienced pathologists without knowledge
of patient characteristics and outcome determined the
results of immunohistochemical staining under mi-
croscopy. Both the primary tumor and LN specimen
were subjected to study, and positive CK19 expression
was defined as ≥5% of tumor/LN cells stained positive
for CK19 [15].
Statistical analysis
The statistical analysis was performed with IBM SPSS
Statistics 21 (IBM Corporation, Software Group, Somers,
NY, USA). Fisher’s exact test and Pearson’s χ2 test were
used to analyze categorical data. Student’s t test was
used to analyze quantitative variables. Overall survival
(OS) was defined by the time elapsing from the date of
diagnosis to either the date of death or the date of the
last contact. Cases with surgical mortality, defined as
death within one month of surgery, were excluded from
the survival analyses. Kaplan-Meier analysis was used to
determine the OS. The log-rank test and Cox regression
multivariate analysis were applied to determine prognos-
tic significance of clinic pathological variables. Statistical
significance was defined as P <0.05.
Results
There were 34 (80.95%) males and 8 (19.05%) females.
Twenty-eight (66.67%) patients were HBV carriers and 9
Table 1 The relationship between clinicopathological variables and CK19 expression in hepatocellular carcinoma
Hepatocellular carcinoma, n = 42
CK19 liver a CK19 lymph node b
Negative Positive (%) P value Negative Positive (%) P value
Age (yr)
≦60 24 5 (17.2) 0.275 26 3 (10.3) 0.497
>60 9 4 (30.8) 11 2 (15.4)
Gender
Male 26 8 (23.5) 0.443 30 4 (11.8) 0.673
Female 7 1 (12.5) 7 1 (12.5)
Hepatitis B virus
Positive 24 4 (14.3) 0.117 26 2 (7.1) 0.197
Negative 9 5 (35.7) 11 3 (21.4)
Hepatitis C virus
Positive 7 2 (22.2) 0.633 8 1 (11.1) 0.712
Negative 26 7 (21.2) 29 4 (12.1)
Total bilirubin(mg/dl)c 1.348 ± 2.373 0.844 ± 0.335 0.533 1.303 ± 2.236 0.760 ± 0.270 0.595
Alkaline phosphotase (U/L)c 111.4 ± 70.447 93.86 ± 30.905 0.527 111.63 ± 68.54 85.40 ± 26.444 0.408
Preoperative α-fetoprotein (ng/ml)c 8300 ± 39207 669.42 ± 1258 0.589 7594 ± 37510 1033 ± 1525 0.701
Child-Pugh classification
A 32 9 (21.9) 0.786 36 5 (12.2) 0.881
B 1 0 (0) 1 0 (0)
Size (cm) 9.027 ± 5.2192 6.156 ± 3.0121 0.124 8.519 ± 5.1876 7.620 ± 2.7472 0.708
T stage
T1/T2 13 5 (27.8) 0.524 16 2 (11.1) 0.688
T3/T4 20 4 (16.7) 21 3 (12.5)
N stage
N0 24 2 (7.7) 0.005 26 0 (0) 0.002
N1 9 7 (43.8) 11 5 (31.3)
Encapsulation
Yes 19 1 (5) 0.013 19 1 (5) 0.203
No 14 8 (36.4) 18 4 (18.2)
Tumor rupture
Yes 4 0 (0) 0.366 4 0 (0) 0.590
No 29 9 (23.4) 33 5 (13.2)
Vascular invasion
Yes 12 4 (25) 0.471 12 4 (25) 0.061
No 21 5 (19.2) 25 1 (3.8)
Daughter nodules
Yes 13 3 (18.75) 0.529 15 1 (6.25) 0.359
No 20 6 (23.07) 22 4 (15.4)
Resection margin
Positive 4 1 (20) 0.606 5 0 (0) 0.284
Negative 29 8 (21.6) 32 5 (13.5)
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Table 1 The relationship between clinicopathological variables and CK19 expression in hepatocellular carcinoma
(Continued)
Edmonson and Steiner grade
I/II 15 4 (21.1) 0.180 18 1 (5.3) 0.341
III/IV 18 5 (21.7) 19 4 (17.4)
a Immunohistochemical staining of primary liver tumor specimen for CK19.
b Immunohistochemical staining of lymph nodes specimen for CK19.
c Data are presented as mean±standard deviation.
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severity of liver cirrhosis, 41 (97.62%) patients were
Child-Pugh classification A whereas only one patient
(2.38%) had Child-Pugh classification B liver cirrhosis. In
terms of tumor T stage, there were 12 (28.57%) T1, 6
(14.29%) T2, 18 (42.86%) T3, and 6 (14.29%) T4 patients.
Table 1 summarizes the relationship between clinico-
pathological variables and CK19 expression in HCC.
CK19 expression was positive in nine (21.43%) primary
liver tumor specimens and five (11.90%) regional LNs;
immunopositivity of CK19 in primary liver tumor was
significantly correlated with CK19 expression in LN
(Spearman correlation coefficient 0.704, P <0.001).
Statistical analysis showed that LNM (Spearman corre-
lation coefficient 0.427, P = 0.005) and tumor non-
encapsulation (Spearman correlation coefficient 0.382,
P = 0.013) were significantly related to CK19 expression
in primary liver tumor. On the other hand, patient age,
gender, cigarette smoking, alcohol consumption, hepa-
titis viral status, preoperative total bilirubin, preope-
rative AFP, preoperative alkaline phosphatase (ALK-P),
Child-Pugh classification, tumor size, T stage, tumor
rupture, vascular invasion, daughter nodules, andFigure 1 The overall survival (OS) of hepatocellular carcinoma (HCC) w
solid line represents HCC without CK19 expression in primary liver tumor a
liver tumor. The horizontal axis is the survival in months and the vertical ax
(95% CI 2.942 to 15.798) months for tumor with CK19 expression and 28.96
expression (P = 0.026). HCC with CK19 expression in primary liver tumor hahistologic grade were not related to CK19 expression in
primary liver tumor.
As for lymph node examination, five (11.90%) patients
had at least one regional LN positive for CK19 expression,
and they all had CK19 expression in their primary liver
tumor. All CK19 (+) LN were metastatic LN (N1 disease).
CK19 expression in regional lymph node was therefore
significantly correlated with LNM (Spearman correlation
coefficient 0.469, P = 0.002). All of the other clinicopa-
thological factors were not related to CK19 expression in
regional LN.
Of 42 patients, 26 (61.9%) patients died during the
follow-up period, including one patient who died
from acute respiratory failure unrelated to HCC or liver
cirrhosis. The 5-year OS rate was 32.5%, with median
survival time of 22.08 months. Patients with CK19 (+)
primary liver tumor or CK 19(+) LN had significantly
poorer overall survival than those without CK19 expres-
sion (for primary liver tumor, 9.37 ± 3.28 (2.942 to 15.798)
months versus 28.96 ± 20.96 (0 to 70.039) months, P =
0.026, and for LN, 9.37 ± 3.17 (3.165 to 15.575) months
versus 28.96 ± 12.92 (3.642 to 54.278) months, P = 0.007,
respectively) (Figures 1 and 2). The 5-year OS rates forith and without CK19 expression in primary liver tumor. The
nd the dashed line represents HCC with CK19 expression in primary
is is the percentile cumulative survival. The median OS was 9.37 ± 3.28
± 20.96 (95% CI 0 to 70.039) months for tumor without CK19
d a significantly poorer OS.
Figure 2 The overall survival (OS) of hepatocellular carcinoma (HCC) with and without CK19 expression in regional lymph nodes (LN).
The solid line represents LN without CK19 expression and the dashed line represents LN with CK19 expression. The horizontal axis is the survival
in months and the vertical axis is the percentile cumulative survival. The median OS was 9.37 ± 3.17 (95% CI 3.165 to 15.575) months for LN with
CK19 expression and 28.96 ± 12.92 (95% CI 3.642 to 54.278) months for LN without CK19 expression (P = 0.007). HCC with CK19 expression in
regional LN had a worst prognosis in terms of OS.
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LN were 11.1% and 0%, respectively, while those for CK19
(−) primary liver tumor or CK19(−) LN were 45.8% and
43.3%, respectively. Vascular invasion (P = 0.005), daughter
nodules (P = 0.009), positive resection margin (P = 0.029),
and AJCC tumor stage (P = 0.020) significantly decreased
overall survival for HCC (Table 2). In patients with N1
disease, although not statistically significant yet, CK19
expression in metastatic LN decreased the OS months
(9.37 ± 3.17 versus 27.88 ± 8.25, P = 0.068). After clas-
sifying these N1 patients into three groups based on the
expression of CK19 in primary liver tumor, we found that
patients with CK19(+) LNM and CK19(+) primary tumor
had a significantly poorer OS than patients with CK19(−)
LNM and CK19(−) primary tumor (P = 0.042) (Figure 3).
Cox regression analysis demonstrated that CK19 expres-
sion in regional LN (HR: 5.695 (1.85 to 17.52), P = 0.002)
and daughter nodules (HR: 2.573 (1.50 to 4.40), P = 0.01)
were independent poor prognostic factors for overall
survival. CK19 expression in primary liver tumor, on the
other hand, was not a significant independent prognostic
factor after Cox regression analysis (Table 3). Figure 4 is
the immunohistochemical microphotograph of primary
liver tumor and regional LN.
Discussion
During development of human liver, hematopoietic stem
cells first differentiate into hepatic stem cells (hepatoblasts),
then hepatic progenitor cells (HPC), and finally hepatocytes
or biliary epithelial cells [19-21]. Cytokeratins, on the other
hand, are typical epithelial cell markers that are expressed
in a tissue-specific and differentiation-dependent manner[22]. Differences in cytokeratin expression are routinely
used to determine the primary cells of origin of malignant
tumor [23,24]. In normal human liver, hepatocytes express
CK8 and CK18, while biliary epithelial cells express CK7
and CK19 [25]. Hepatic progenitor cells, on the other hand,
express markers specific for both hepatocytes and biliary
epithelial cells. As progenitor cells differentiate into differ-
ent cell lineages, they lose specific phenotypic characteris-
tics. For example, CK19 is first lost when hepatic
progenitor cells differentiate into hepatocyte lineage [14]. In
other words, tumor cells of HCC should not express CK19
if they originate from hepatocytes. However, the current
study and several previous reports showed that some
HCC can express CK19, the marker specific for biliary
epithelial cells [14,15,26-30]. These consistent findings
suggested that some HCC may develop from, instead of
hepatocytes directly, but hepatic progenitor cells which
express CK19 [14,25,31,32]. An earlier study that focused
on immunohistologic expression of HCC patients who
received hepatectomy indicated that about 10% of HCC
with typical microscopic histologic features had cholangio-
cellular characteristics [14]. The study employed CK19
expression as the cholangiocellular marker and con-
cluded that the cholangiocellular-marker positive HCC
may originate from hepatic progenitor cells, or they
may acquire the characteristics of cholangiocellular
epithelium by metaplasia. Further studies are warranted
to investigate the carcinogenesis of this special HCC
subtype.
Our study found that CK19 expression in primary liver
tumor was associated with a higher incidence of LNM
and tumor non-encapsulation. An earlier published work
Table 2 Univariate analyses of factors associated with overall survival in hepatocellular carcinoma after hepatectomy
Median survival (months)a 5-year OS rate (%) P value
Age (yr)
≦60 28.96 ± 3.98 (21.165 to 36.755) 40.4 0.338
>60 15.02 ± 19.37 (0 to 52.977) 34.6
Gender
Male 22.68 ± 5.44 (12.020 to 33.340) 30.1 0.068
Female 28.14 ± 6.45 (15.491 to 40.789) 62.5
Alcohol
Yes 19.40 ± 7.87 (3.968 to 34.832) 18.5 0.027
No 47.08 ± 32.31 (0 to 110.413) 46.6
Hepatitis B virus
Positive 28.96 ± 3.74 (21.630 to 36.290) 40.3 0.332
Negative 17.72 ± 3.66 (10.556 to 24.884) 32.7
Hepatitis C virus
Positive 47.08 ± 38.99 (0 to 123.488) 41.7 0.665
Negative 28.14 ± 5.04 (18.265 to 38.015) 37.2
Preoperativeα-fetoprotein (ng/ml)
≦20 61.91 ± 31.65 (0 to 123.934) 51.3 0.847
>20 27.88 ± 6.69 (14.772 to 40.988) 33.4
Child-Pugh classification
A 28.96 ± 7.08 (15.086 to 42.834) 38.7 0.461
B 19.40 ± 0 (−− to --) 0
Size (cm)
≦5 61.91 ± 34.99 (0 to 130.486) 58.3 0.310
>5 22.68 ± 5.46 (11.988 to 33.372) 30.7
Encapsulation
Yes 47.08 ± 28.79 (0 to 103.515) 48.6 0.122
No 19.10 ± 3.34 (12.551 to 25.649) 28.6
Tumor rupture
Yes 27.88 ± 4.99 (18.105 to 37.655) 32.9 0.206
No 80.55 ± 46.93 (0 to 172.539) 75.0
Vascular invasion
Yes 17.72 ± 4.26 (9.373 to 26.067) 9.0 0.005
No 61.91 ± 31.46 (0.240 to 123.58) 51.3
Daughter nodules
Yes 17.72 ± 8.14 (1.760 to 33.680) 10.8
No 47.08 ± 26.69 (0 to 98.611) 48.6 0.009
Resection margin
Positive 7.63 ± 2.17 (3.379 to 11.881) 20.0 0.029
Negative 32.71 ± 9.00 (15.067 to 50.353) 40.1
Liver cirrhosis
Positive 28.96 ± 8.66 (11.981 to 45.939) 41.0 0.791
Negative 22.68 ± 9.37 (4.322 to 41.038) 33.3
Lee et al. World Journal of Surgical Oncology 2013, 11:136 Page 6 of 11
http://www.wjso.com/content/11/1/136
Table 2 Univariate analyses of factors associated with overall survival in hepatocellular carcinoma after hepatectomy
(Continued)
Edmonson and Steiner grade
I 36.91 ± 36.64 (0 to 133.736) 60.0 0.063
II 80.55 ± 32.99 (15.895 to 145.205) 60.0
III 22.68 ± 5.46 (11.978 to 33.382) 24.2
IV 17.72 ± 3.20 (11.443 to 23.997) 0
Stage
I 101.98 ± 0 (−− to --) 55.6 0.020
II 61.91 ± 22.30 (18.198 to 105.622) 75.0
III 19.40 ± 3.33 (12.873 to 25.927) 22.5
IV 11.34 ± 6.12 (0 to 23.326) 0
CK19 liver b
Positive 9.37 ± 3.28 (2.942 to 15.798) 11.1 0.026
Negative 28.96 ± 20.96 (0 to 70.039) 45.8
CK19 LN c
Positive 9.37 ± 3.17 (3.165 to 15.575) 0 0.007
Negative 28.96 ± 12.92 (3.642 to 54.278) 43.3
a Median survival±standard error (95% confidence interval).
b Immunohistochemical staining of primary liver tumor specimen for CK19.
c Immunohistochemical staining of lymph nodes specimen for CK19.
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very low incidence, tended to be an infiltrating type of
HCC and carried an extremely poor prognosis [12]. A
study from our group also indicated that HCC encapsu-
lation was associated with less vascular invasion and was
a significant prognostic factor for better outcome in
larger HCC. These studies suggested that LNM and
tumor non-encapsulation were significant indicators for
HCC invasiveness and poor outcome. In other words,
CK19 expression of primary liver tumor may possiblyFigure 3 The overall survival (OS) of N1 hepatocellular carcinoma (HC
nodes (LN). The solid line represents the OS of CK19 (−) primary liver tum
represents that of CK19(+) primary liver tumor with CK19(+) LNM. The horiz
percentile cumulative survival. The median OS of patients with CK19(+) LN
CK19(−) LNM and CK19(−) primary tumor (P = 0.042). CK19 expression in mindicate the worse prognosis for the patient. The survival
analysis from the current study further strengthened this
implication. Reports done by groups in China and by
others stated that increased expression of CK19 in HCC
was significantly correlated with LNM and a poorer
outcome [14,16,17]. CK19 expression by HCC was also
suggested to be a predictor of early postoperative recur-
rence and was associated with increased invasiveness
and lymph node metastasis [16]. Studies focused on
molecular classification and diagnosis of HCC alsoC) patients with and without CK19 expression in regional lymph
or with CK19(−) lymph node metastasis (LNM) and dashed line
ontal axis was the survival in months and the vertical axis was the
M and CK19(+) primary tumor was significantly poorer than those with
etastatic LN was a poor prognostic factor for HCC with LNM.
Table 3 Multivariate analyses of factors associated with
overall survival in hepatocellular carcinoma after
hepatectomy
Multivariate analysis
Hazard ratio (95% CI) P value
Daughter nodules 2.573 (1.50 to 4.40) 0.001
CK19 LNa 5.695 (1.85 to 17.52) 0.002
aImmunohistochemical staining of lymph nodes specimen for CK19.
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of aggressive and advanced HCC [33,34]. Our findings
were consistent with these reports and we concluded
that: (1) CK19 expression in primary liver tumor was
an indicator of HCC invasiveness including LNM and
non-encapsulation, and (2) CK 19 expression in pri-
mary liver tumor was a poor prognostic factor for over-
all survival.
Several studies, including the aforementioned ones,
demonstrated the impact of CK19 expression by primary
tumor on HCC outcome [14-17,25,33,34]. Nevertheless,
few investigated the molecular signature of metastatic
LN and the influence of these specific molecules on
HCC outcome. Our study was the first one in the
literature to examine the expression of CK19 by re-
gional LN of HCC. The expression of CK19 in regional
LN, which usually did not have epithelial cells, may
indicate that the CK19(+) primary liver tumor cell had
metastasized from liver to regional LN. We found that
seven out of nine (77.8%) CK19 (+) HCC had LNM,
and all patients who had positive CK19 expression in
their LN (five patients) were also positive for CK19
expression in primary liver tumor. Therefore, we sug-
gested that HCC with immunopositivity of CK19,
meaning presence of hepatic progenitor cells, had a high
propensity for LNM.
Our study shows that CK19 expression in primary
liver tumor or regional LN was associated with poorer
overall survival. However, after Cox regression multivari-
ate analysis, only CK19 expression in LN (HR: 5.695
(1.85 to 17.52), P = 0.002) and the presence of daughter
nodules (HR: 2.573 (1.50 to 4.40), P = 0.01) were inde-
pendent poor prognostic factors for overall survival. In
addition, in patients with LNM, CK19 expression in
metastatic LN significantly decreased the overall sur-
vival, when compared with CK19(−) LNM in CK19(−)
primary liver tumor. Subgroup analysis found that there
was no significant difference between CK19 (+) LNM
and CK19(−) LNM regarding most major clinicopatho-
logical factors. This indicated that the worst prognosis of
CK19 (+) LNM was not attributed to other prognostic
factors, but only to CK19 expression in metastatic LN.
Our study, therefore, was the first report in the English
literature to demonstrate the worst prognostic impact of
CK19 (+) LNM on HCC after hepatectomy. The natureof CK19 (+) primary liver tumor with CK19(−) meta-
static LN remains uncertain and mandates further inves-
tigation. As shown above, HCC with LNM carried a
poor outcome [12]. Our study further explored the
possibility that HCC with CK19(+) metastatic LN may
be an HCC subtype with even worse prognosis. How-
ever, with appropriate treatment and follow-up, this
subset of patients still can achieve a median overall
survival of 9.37 ± 3.17 months after hepatectomy. Our
earlier study demonstrated that LNM may not be a
contraindication for curative resection for HCC. A more
aggressive surgical treatment including lymph node
dissection was suggested when LNM was suspected [12].
The present study echoed that finding and we further
suggested that CK19 immunohistochemical staining of
primary liver tumor and dissected LN should be perfor-
med after hepatectomy to determine LN status and to
predict outcome.
This study had some drawbacks. First, the rarity of
HCC with LNM resulted in a small sample size and
rendered statistical analysis difficult. We believe that
with a larger sample size, our findings will become even
more significant and persuasive. Second, since this study
was a retrospective hospital-based analysis, incomplete
data collection were inevitable when reviewing records
from a very long time ago. Selection bias might also exist
when enrolling patients into this study. In addition,
there is fundamental problem in using immunohisto-
chemical staining in evaluating the expression profile of
CK19. It requires experienced histopathologists for
staining and interpreting the immunohistochemical
examination result. Other techniques, including poly-
merase chain reaction, could be more objective and
sensitive. Therefore, a well-designed prospective study
with long-term follow-up is required to further validate
our study.
Conclusions
In conclusion, our study showed that (1) CK19 expression
in primary liver tumor is an indicator of HCC invasiveness
including LNM and non-encapsulation, (2) CK19 expres-
sion in metastatic LN of primary HCC iss associated with
an extremely poor outcome after operation, and (3) CK19
immunohistochemical staining of primary liver tumor and
regional LN should be performed after hepatic resection
to determine LN status and to predict outcome. Since
CK19 was considered a marker of hepatic progenitor cells
and biliary epithelial cells, the subset of HCC expressing
CK19 in metastatic LN may represent an HCC category
that originates from HPC or by metaplasia and carries an
extremely poor prognosis. It is of clinical significance to
identify these patients at risk for more aggressive surgical
treatment and postoperative follow-up. A recent study
also indicated that the activation of the epidermal growth
Figure 4 Immunohistochemical microphotograph of primary liver tumor (left column: A, C, E, G, and I) and regional lymph nodes (LN)
(right column: B, D, F, H, and J) for CK19 expression. A and B) CK19 (+) primary liver tumor with CK19 (+) lymph node metastasis (LNM). The
cytoplasmic staining of CK19 can be demonstrated in both primary tumor and metastatic LN. C and D) CK19 (+) primary liver tumor with CK19(−)
LNM. The regional lymph nodes had been infiltrated by metastatic tumor cells, which did not express CK19. E and F) CK19 (+) primary liver
tumor without LNM. The normal LN structure can be clearly identified. G and H) CK19 (−) primary liver tumor with CK19(−) LNM. Both the
primary tumor and metastatic LN did not express CK19 in their cytoplasm. On the other hand, the biliary epithelial cells expressed CK19. I and J)
CK19(−) primary liver tumor without LNM. (Magnifications, x100).
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http://www.wjso.com/content/11/1/136factor (EGF)-EGF receptor signaling pathway is associ-
ated with the development of CK19 (+) HCC, and this
pathway may account for the poor prognosis of patients
[35]. The mechanism by which EGFR signaling pathway
induces CK19 expression remains unknown. Further
studies are warranted to elucidate the carcinogenesis of
this subset of HCC.
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